BioMedWire Editorial Coverage: Multiple sclerosis ('MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost.
Companies in search of well-kept space at less-than-trophy rents are seeking more Class B office space than before while ...
J Batt’s first leadership team hire at Kentucky is the administrator who has been leading the Michigan State department since ...
The Nationwide Investor Destinations Funds saw positive returns in Q2 2026 amid an equity rally. Read the full analysis for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results